A mitochondria-targeting peptide studied for its role in cellular energy production. FDA-approved in 2025 for one rare disease, and investigational for everything else.
SS-31, known in clinical development as elamipretide and earlier as MTP-131 or Bendavia, is a small synthetic peptide built to concentrate inside mitochondria, the structures that generate most of a cell's usable energy. It's one of the more precisely understood compounds in this whole space. In September 2025 it became the first mitochondria-targeted therapy the FDA has ever approved, under the brand Forzinity, for an ultra-rare pediatric disease called Barth syndrome. Barth syndrome is a rare genetic condition, mostly affecting boys, where a faulty gene disrupts cardiolipin (the same inner-membrane lipid SS-31 binds), which weakens the heart and skeletal muscles and causes deep fatigue. That's not a coincidence. It's close to the cleanest test case there is for what SS-31 is supposed to do, which is stabilize cardiolipin. That approval is narrow, and it matters that you understand how narrow. For the aging, energy, and performance reasons most people come looking for SS-31, the human evidence is early, and in several large trials it hasn't held up. This page is here to give you both halves of that picture honestly.
A four-amino-acid peptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that carries a positive charge and builds up strongly inside mitochondria. It was designed by researchers Hazel Szeto and Peter Schiller, which is where the "SS" comes from, and taken through clinical trials by Stealth BioTherapeutics as elamipretide. Because it targets a basic piece of cell biology rather than one disease pathway, it's been tested across a wide range of conditions. The approved prescription form is Forzinity. The material sold online as a "research compound" is not that approved product.
The biological context for SS-31 centers on mitochondrial function, skeletal muscle, and cardiac muscle, the tissues that lean hardest on a steady supply of energy. The connecting thread is cardiolipin, a lipid in the inner mitochondrial membrane that helps hold the energy-producing machinery in shape and that tends to degrade with age and illness. This is a systems-level orientation, not proof that the compound changes those systems in a given person. Mechanism, model data, and human evidence belong in separate lanes, and this page keeps them there.
Mitochondria have an inner membrane rich in a distinctive lipid called cardiolipin, which helps hold the energy-producing machinery in the right shape. Cardiolipin tends to break down with age and in disease, and when it does, energy output falls and cells throw off more reactive byproducts. SS-31 binds to cardiolipin and appears to stabilize that inner-membrane structure. In lab and animal work, that's linked to better-preserved energy production and less oxidative stress. It was first described as an antioxidant, but later research points to the membrane-stabilizing role as the bigger part of the story. Here's the framing that matters, though: a well-understood mechanism is not the same thing as a proven benefit in people. SS-31 is actually a textbook example of that gap.
Human data. In its approved indication, Barth syndrome, the pivotal trial (TAZPOWER) tested it in a very small group of patients, measuring things like muscle strength and how far people could walk, and the clearest functional improvements showed up over longer open-label follow-up rather than in the short blinded comparison. In healthy older adults, a randomized trial found that a single dose improved a measure of muscle mitochondrial energy production. But that was a surrogate marker, one dose, in 39 people specifically chosen for already having poorly functioning mitochondria. And in a full phase 3 trial in primary mitochondrial myopathy (MMPOWER-3, 218 patients), it did not meet its primary endpoints. Heart failure and macular degeneration programs have also missed their primary endpoints along the way. The honest summary is real mechanism, one narrow and provisional approval, and a mixed-to-disappointing record in the bigger controlled trials.
Preclinical data. Much of the underlying rationale comes from laboratory and animal work, where binding to cardiolipin has been associated with better-preserved energy production and lower oxidative stress in stressed or aged mitochondria. That preclinical layer helps explain why the compound was worth testing in people, but it does not establish human outcomes on its own. Model findings point toward plausible biology; they are not a substitute for controlled human trials.
Anecdotal discussion. Online discussion of SS-31 often blends the approved drug with a version sold as a research compound and treats early or mechanistic findings as if they were settled results. Anecdote can explain why the topic is visible, but it cannot establish product quality, safety, or real-world effect. It is weakest here precisely because the material sold as a research chemical is not the FDA-approved product and has not been through the same controls.
A few things shape how much weight to put on the positive findings. The approval rests on an intermediate endpoint and may hinge on a confirmatory trial. The strongest human signals come from tiny samples, since Barth syndrome affects roughly 150 people in the US and the aging study tested just 39, and only once rather than over time. Several of the larger, better-powered trials simply didn't work. And there's a "right patient" pattern in the data, where the compound seems to help most when the energy machinery is intact but its membrane environment is damaged, and less when the machinery itself is broken. None of this is settled science.
In the trials run so far, the most commonly reported issue was reactions at the injection site, generally mild to moderate, and the compound has been described as well tolerated in those studies. Keep in mind that this safety data comes from monitored clinical settings using the pharmaceutical-grade drug, not from unregulated research-chemical versions of unknown quality. Nothing on this page is medical advice.
SS-31 reaches performance and longevity conversations because mitochondrial energy output sits underneath endurance, recovery, and how people feel day to day. That interest is understandable, but the compound should not be read as a performance or anti-aging tool. Its one approval is for a single rare disease, and the aging-and-energy human work so far is early, small, and mixed. The most useful role for this page is orientation: it explains why SS-31 shows up in these discussions and why early findings deserve restraint rather than excitement.
Across the Aeternus library, the practical standard is claim matching. A mechanism belongs in mechanism language, a cell or animal model belongs in preclinical language, and a human trial belongs in population-specific human-evidence language. This keeps the entry useful for readers who want orientation without turning biology into personal direction. The strongest interpretation is usually the narrowest accurate one: name the pathway, name the evidence type, name the limits, and leave space for uncertainty where the sources do not answer the question. That standard also protects the reader from a common mistake in this category: assuming that biological relevance automatically creates a usable strategy. It does not. Evidence becomes useful when the claim, source type, population, endpoint, and safety context all line up.
It isn't a proven energy or anti-aging treatment. The one thing it's approved for is a single ultra-rare genetic disease, and being approved for that says nothing about fatigue, athletic recovery, longevity, or general "mitochondrial health." The version sold as a research compound isn't the FDA-approved prescription product and hasn't been through the same quality controls. This page doesn't tell you how to get it or use it, and nothing here is a nudge to do either.
We find SS-31 genuinely interesting, partly because the biology underneath it is so clear, and partly because it's an honest lesson in how a real mechanism doesn't automatically turn into a real-world benefit. The most useful thing we can do is show you the whole thing: the elegant science, the first-ever approval in its class, and the run of large trials that fell short. If you take one idea from this page, make it this. "Well understood" and "proven for what I want" are two different things, and SS-31 sits right on the line between them.
